ARQ 197

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-small-cell Lung Cancer

Conditions

Non-small-cell Lung Cancer

Trial Timeline

May 1, 2012 → Apr 1, 2015

About ARQ 197

ARQ 197 is a phase 2 stage product being developed by Kyowa Kirin for Non-small-cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01580735. Target conditions include Non-small-cell Lung Cancer.

What happened to similar drugs?

7 of 20 similar drugs in Non-small-cell Lung Cancer were approved

Approved (7) Terminated (6) Active (9)
Gefitinib + DocetaxelAstraZenecaApproved
PembrolizumabMerckApproved
zoledronic acidNovartisApproved
AtezolizumabRocheApproved
Erlotinib + ChemotherapyRocheApproved
LorlatinibPfizerApproved
Pemetrexed + ErlotinibHikma PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01656265Phase 1Completed
NCT01580735Phase 2Completed
NCT01152645Phase 2Completed

Competing Products

20 competing products in Non-small-cell Lung Cancer

See all competitors